Yara Alenazi
Investor, HealthTech at MassMutual Ventures
Yara Alenazi
Investor, HealthTech at MassMutual Ventures
United Kingdom
Overview
Work Experience
Venture House Advisory Board
2024 - Current
Investor, HealthTech
2022
HealthTech investing across Europe & APAC
Board Observer
2023
Board Observer
2023
Board Observer
2023
TechBio Chapter Champion - BioCapital Network
2024
The BioCapital Network is an international community of over 275 investors, representing over 170 unique funds and several Angels across 20+ countries, all actively backing UK-based life science companies. The community aims to provide a medium for life science investors to network, develop meaningful relationships, share high-quality deal flow, open co-investment opportunities and enable discussions on the latest industry trends and challenges. Through our online community platform and regular events, I support the growth of the TechBio Chapter.
Member
2024
Mentor
2024 - 2024
The first Saudi Hackathon in London held at the Royal Embassy of Saudi Arabia Cultural Bureau. This event, aligned with Saudi Vision 2030, brought together Saudi students in the UK to promote creativity and innovation. Participants collaborated on developing cutting-edge solutions across various disciplines, with top projects receiving recognition and awards. The hackathon provided an excellent platform for showcasing the talents and innovative spirit of Saudi students. https://www.spa.gov.sa/N2118856
Investment Analyst
2020 - 2022
Led due diligence on 10 investments, including OrganOx Ltd., SpyBiotech Ltd., OxSonics Ltd., and BibliU Ltd. Day to day management of portfolio companies, including Orthox Ltd., OthoSon Ltd., Momentum Bioscience Ltd., Orbit Discovery Group Ltd., T-Cypher Bio Holdings Ltd., Osler Diagnostics Ltd., OxSonics Ltd., Oxford Endovascular Ltd., OrganOx Ltd., and SpyBiotech Ltd.
Board Observer
2020 - 2022
Momentum Bioscience is developing SepsiSTAT®, a direct-from-blood diagnostic test system for determining the presence or absence and characteristics of viable bacteria and yeast in <3 hours. The test aims to rapidly triage sepsis patients and allow clinicians to make faster and better-informed antibiotic decisions, increasing the efficacy of therapies and improving antibiotic stewardship.